| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Rhythm Pharmaceuticals (NASDAQ:RYTM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 3 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Rhythm Pharmaceuticals, presenting an average target of $44.86, a high estimate of $55.00, and a low estimate of $29.00. Witnessing a positive shift, the current average has risen by 21.7% from the previous average price target of $36.86.
The perception of Rhythm Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joseph Stringer | Needham | Raises | Buy | $50.00 | $45.00 |
| Jeffrey Hung | Morgan Stanley | Raises | Overweight | $55.00 | $29.00 |
| Derek Archila | Wells Fargo | Raises | Overweight | $53.00 | $48.00 |
| Corinne Jenkins | Goldman Sachs | Raises | Buy | $42.00 | $38.00 |
| Joseph Stringer | Needham | Raises | Buy | $45.00 | $32.00 |
| Derek Archila | Wells Fargo | Raises | Overweight | $40.00 | $38.00 |
| Jeffrey Hung | Morgan Stanley | Raises | Equal-Weight | $29.00 | $28.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Rhythm Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Rhythm Pharmaceuticals analyst ratings.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Rhythm Pharmaceuticals displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 425.3%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -196.25%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -23.26%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Rhythm Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -13.3%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Rhythm Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: RYTM
